Cancer

July 20, 2017

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: Dihydroartemesian (DHA), a derivative of Artemesian isolated from Artemesia annua L., inhibits the expression of PD-L1, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 21/July/2017, 12.14 am

Introduction:What they say: A recent study from Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA shows […]
July 19, 2017

Molecular therapy for glioblastoma: Cantharidin inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down regulation of its target gene, 20/July/2017, 12.07 am

Introduction: What they say: A study from the Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Ohio, USA shows that “Transcription elongation factors represent in vivo […]
July 19, 2017

Natural product-derived therapy for prostate cancer: Eriocitrin, one of the components of Lemons, inhibits the expression of mTORC1 and its downstream target AMD1, dismantles mTORC1-AMD1 signaling network, decreases polyamine levels, and inhibits prostate cancer progression via up regualtion of its target gene, 19/July/2017, 11.54 pm

Introduction: What they say: A study from CIC bioGUNE (Center for Cooperative Research in Biosciences), Bizkaia Technology Park, 801 Building, 48160 Derio, Spain shows that “mTORC1-dependent AMD1 regulation sustains polyamine […]
July 18, 2017

Natural product-derived therapy for prostate cancer: Dihydroartemisinin(DHA), a derivative of Artemisinin present in Artemesia Annua L, inhibits the expression of mTORC1 and its downstream target AMD1, dismantles mTORC1-AMD1 signaling network, decreases polyamine levels, and inhibits prostate cancer progression via up regualtion of its target gene, 18/July/2017, 11.53 pm

Introduction: What they say: A study from CIC bioGUNE (Center for Cooperative Research in Biosciences), Bizkaia Technology Park, 801 Building, 48160 Derio, Spain shows that “mTORC1-dependent AMD1 regulation sustains polyamine […]